Search PubMed⌕ Search

Biomedical subjects

J Lumbroso

Publications and source records attributed to J Lumbroso.

At least 91 records · Page 5Linked to original sources
PubMed1983

Relationship between thyrotropin stimulation and radioiodine uptake in lung metastases of differentiated thyroid carcinoma.

To examine whether the injection of bovine TSH (bTSH) produces maximal radioactive iodine uptake (RAIU) in lung metastases in patients with differentiated thyroid cancer, 10 patients were studied 12 times. In 10 of these studies, an initial RAIU measurement was performed immediately after 3 injections of 10 IU bTSH given immediately after T3 withdrawal. Another RAIU measurement was performed 7-19 days after T3 withdrawal. Uptake increased in all patients even when it was clearly detectable immediately after bTSH stimulation. Thus, 3 days of bTSH stimulation in these patients did not lead to maximal 131I uptake, and it could only be reached after prolonged endogenous TSH stimulation. bTSH was not injected in the 2 other patients, in whom 6 RAIU measurements were carried out. Radioiodine uptake increased with time in both patients. It appears that both the level of endogenous TSH and the length of stimulation play a determining role in RAIU. This might explain why 3 days of bTSH stimulation are insufficient to elicit maximal 131I uptake.

Adolescent↗
PubMed1983

[Use of tomographic scintigraphy with radio-labelled monoclonal antibodies for detecting human digestive cancers and medullary cancers of the thyroid].

Two 131-Iodine radiolabelled monoclonal antibodies were used to perform tomoscintigraphy in 42 patients: 11 patients bearing medullary thyroid cancers and 19 patients bearing gastrointestinal cancers received an antibody directed against carcino-embryonic antigen; 12 patients bearing gastro-intestinal cancers received an antibody directed against a non circulating antigen expressed by human colorectal cancers cell lines. Tomoscintigraphy is particularly useful for analysing the complex biodistribution of radiolabelled antibodies and the low contrast images encountered in immunoscintigraphy; the problems related to the true positive rate and to the clinical specificity of the method are discussed.

Antibodies, Monoclonal↗
PubMed1982

[Value of serum thyroglobulin assays in cancers of the thyroid].

Serum thyroglobulin (Tg) assays provide no clue as to the nature of a cold thyroid nodule, but they provide guidelines for isotope exploration tests in differenciated epitheliomas. Undetectable Tg levels during hormonal treatment make these tests unnecessary, while measurable levels in the absence of residual thyroid tissue should encourage investigations for metastases, and the higher these levels the more thorough the investigation. When thyroid residues are present Tg levels are usually within the normal range for a healthy population (2.5-28 ng/ml) and no conclusion can be drawn. The destruction of thyroid residues with Iodine 131 in poor prognosis patients facilitates monitoring by means of Tg assays.

Bone Neoplasms↗
PubMed1982

A co-operative study on the clinical value of dynamic renal scanning with deconvolution analysis.

An international project was set up to study the clinical usefulness of intrarenal transit times derived from the renogram by deconvolution. A common data sheet, to collect clinical, biochemical, radiological and isotopic information, was completed by the centres. Five hundred and ninety-one patients were studied and the results analysed. The mean transit time (MTT) in normal kidneys was found to be 3.6 +/- 1.1 min. If the MTT is greater than 7.6 min, a kidney is likely to be obstructed. In vesico-ureteric reflux, the transit times are prolonged, but they are normal in infection, hypertension, parenchymal disease and minimally irradiated kidneys. In transplantation, when the kidney is normal, the transit times are shorter than in the natural kidney; in acute rejection, transit time are prolonged.

Adult↗
PubMed1976

[Gamma-myelography in neurosurgery].

The gamma-myelography is rapid and riskless investigation whose practice is very easy to perform while doing CSF study. The choice of radioactive tracer in liquid or gaseous phase depends on suspected abnormality. In case of medullar compression, it enables to affirm the diagnosis of block and define its level. It does not enable to know the intra or extradural localization of a lesion. For this reason we often use in the same time a 99mTc stannous pyrophosphates scintigraphy of rachis. Association of these two technics is particularly interesting in case of pressure myelitis due to vertebral metastatic localization. In traumatic pathology, gamma-myelography can be realized in cases of emergency, because of its inocuity and rapidity of its realization (10 min. with use of 133 Xenon).

Brain Diseases↗
PubMedDate not supplied

Therapeutic use of [131I]metaiodobenzylguanidine in neuroblastoma: a phase II study in 26 patients. "Société Française d'Oncologie Pédiatrique" and Nuclear Medicine Co-investigators.

Seven French Medical Centers were involved in a cooperative study evaluating [131I]Metaidobenzylguanidine (131I-MIBG) therapy in advanced neuroblastoma. Children (median age 4 years) had initially a stage III (4 patients) or stage IV (22 patients) neuroblastoma. Before MIBG treatment, 14 patients had a primarily refractory disease, 10 patients were relapsing; in 8 cases, autologous bone marrow transplantation had been performed. Tumour sites were in 24 patients: 13/24 local disease, 8/24 bone metastases, and 7 bone marrow involvement. Catecholamines were elevated in 7/24 patients. The median activity of 131I-MIBG per injection ranged from 30 to 108 mCi; the number of injections varied from 1 to 5. We observed 5/10 pain palliations and 10/24 stabilizations of the disease course for 1 to 7 months with no objective volume tumour response. Haematologic toxicity caused a platelet count less than 150,000/microL in 4 patients, less than 100,000 in 1 patient and less than 50,000 in 7 patients.

3-Iodobenzylguanidine↗
PubMedDate not supplied

Treatment of malignant pheochromocytoma with [131I]metaiodobenzylguanidine: a French multicenter study.

Six Medical Centers in France were involved in a prospective study evaluating the efficacy of [131I]metaiodobenzylguanidine (131I-MIBG) in the treatment of malignant pheochromocytoma. Fifteen patients aged from 28 to 75 years bearing tumor sites demonstrating a good MIBG uptake were included in this study. Catecholamines were elevated in 13/14 cases, VMA in 9/14 and metanephrines in 13/14. Two to 11 therapeutic activities of 131I-MIBG were administered, with a mean number of therapeutic doses per patient of 4 and a mean single activity of 4.7 GBq (range 2.9 to 9.25 GBq). Seven patients were alive, and seven patients died 6 to 29 months after their first MIBG administration (mean follow-up of 36 months); 1 patient was lost to follow-up. Two patients had a partial tumor response only, 4 had a hormonal response only, and 3 had both a partial tumor response and a hormonal response (complete in 2 cases). Six patients did not respond to the treatment, 4 of them died. Of the 9 responding patients, 4 relapsed, 3 of whom died subsequently. Haematological toxicity was always transient and mild, except in 1 case.

3-Iodobenzylguanidine↗